Fremont, Ca., USA — Zosano Pharma, Inc., a privately held pharmaceutical company, announced the appointment of Kleanthis G. Xanthopoulos to its board of directors. [break]
Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc., a company developing microRNA therapeutics. Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. He co–founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director until its acquisition by Roche.
He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals), and participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York.
An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
Dr. Xanthopoulos is a member of the Board of Directors of the - April 16, 2013, Fremont, Ca., USA — Zosano Pharma, Inc., a privately held pharmaceutical company, announced the appointment of Kleanthis G. Xanthopoulos to its board of directors.
Article continues below
]
Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc., a company developing microRNA therapeutics. Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. He co–founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director until its acquisition by Roche.
He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals), and participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York.
An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. ■